CANNAINVESTOR Magazine June 2016 - Page 24

When it comes to medical cannabis, OWC believes in science instead of mythology aiming to produce pharmaceutical-grade cannabis-based products and treatments that are: • Standardized in composition, formulation and dose; • Administered by means of the appropriate and efficient innovative delivery systems • Tested in properly controlled pre-clinical and clinical studies. CANNAINVESTOR Magazine Research One World Cannabis: Research Division for Cannabis Headquartered in Israel, the birthplace of modern medical cannabis research, the Research Division leverages the Company’s extensive network comprising some of Israel’s leading researchers, scientists, universities and hospitals, as well as cannabis breeders and extractors, to study and test the effectiveness of different combinations of cannabinoids in the treatment of disease and chronic conditions. One World Cannabis is focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments specifically designed for several medical conditions, starting with multiple myeloma, psoriasis, fibromyalgia, migraine and PTSD (post-traumatic stress disorder). To date, One World Cannabis completed two of three new innovative delivery systems of active cannabinoids, with its own formulas. The new delivery systems will be safe to use with controlled dosage and long lasting quality. The delivery systems will be clinically tested through OWC’s studies. To date, One World Cannabis has signed three research collaboration agreements with the biggest academic hospital in Israel, which is also the largest hospital in the Middle East. Within the framework of these agreements, the company will initiate pre-clinical and clinical studies to explore the effect of several combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma (a cancer of plasma cells), psoriasis and fibromyalgia. One World Cannabis will continue to collaborate with other industry partners, as well as leading academic medical centers, in order to develop, clinically research, produce, and commercialized novel cannabinoid-based therapies targeting a variety of different indications and effectively help patients in need. Upon the successful completion of clinical trials and the development